BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bover Sanjuán J, Navarro-González JF, Arenas MD, Torregrosa JV, Tamargo Menéndez J, de Francisco ALM, González-Parra E, Lloret Cora MJ, Sánchez Álvarez JE, Martín-Malo A, Molina Vila P, Bajo MA, DaSilva Santos I. Pharmacological interactions of phosphate binders. Nefrologia (Engl Ed) 2018;38:573-8. [PMID: 30473007 DOI: 10.1016/j.nefro.2018.05.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Casado E, Bover J, Gómez-Alonso C, Navarro-González JF. Osteoporosis in chronic kidney disease: A essential challenge. Med Clin (Barc) 2021:S0025-7753(21)00295-5. [PMID: 34154811 DOI: 10.1016/j.medcli.2021.05.007] [Reference Citation Analysis]
2 van Berlo-van de Laar IRF, Prins-Can I, de Lange AA, Taxis K, Jansman FGA. Binding interactions with sevelamer and polystyrene sulfonate in vitro. Pharmacol Res Perspect 2021;9:e00834. [PMID: 34302439 DOI: 10.1002/prp2.834] [Reference Citation Analysis]
3 Favero C, Carriazo S, Cuarental L, Fernandez-Prado R, Gomá-Garcés E, Perez-Gomez MV, Ortiz A, Fernandez-Fernandez B, Sanchez-Niño MD. Phosphate, Microbiota and CKD. Nutrients 2021;13:1273. [PMID: 33924419 DOI: 10.3390/nu13041273] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Sprague SM, Ketteler M. A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemia. Expert Opin Drug Saf 2021;20:1463-72. [PMID: 34511018 DOI: 10.1080/14740338.2021.1978973] [Reference Citation Analysis]
5 Yee J, Rosenbaum D, Jacobs JW, Sprague SM. Small Intestinal Phosphate Absorption: Novel Therapeutic Implications. Am J Nephrol 2021;52:522-30. [PMID: 34515051 DOI: 10.1159/000518110] [Reference Citation Analysis]
6 Sprague SM, Martin KJ, Coyne DW. Phosphate Balance and CKD-Mineral Bone Disease. Kidney Int Rep 2021;6:2049-58. [PMID: 34386654 DOI: 10.1016/j.ekir.2021.05.012] [Reference Citation Analysis]